Baxter said it would spin off its drug business into an independent company next year, the latest move by a major diversified health-care concern to shed product lines considered vulnerable to competition.
from WSJ.com: US Business http://ift.tt/1eUcWzU
via IFTTT
from WSJ.com: US Business http://ift.tt/1eUcWzU
via IFTTT
No comments:
Post a Comment